Pfizer Inc. (PFE) Announces Detailed Results Of OPT Compare Phase 3 Study Of Tofacitinib 5 Mg And 10 Mg Twice Daily Compared To High-Dose ENBREL® In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
3/24/2014 8:39:58 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib, the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Top-line results from OPT Compare were previously announced in October 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by